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Of the many anti-emetic drugs developed in the last 15
years, the antihistamines and phenothiazines are the most
widely used.1.2 It has been estimated that reactions such
as drowsiness, hypotension dizziness, and :insomnia 'Occur
in 20 -75% of all patients receiving anti-emetic therapy.
Most of these drugs possess side-effects of varying degrees
and their severity is often proportional to the dosage.3
PHARMACOLOGY
This study was undertaken to assess the efficacy or other-
wise of a new anti-emetic drug, trimethobenzamide, in 35
patients with nausea and vomiting of pregnancy. This drug
is a substituted benzamide. The principal pathway for its
anti-emetic action is essentially the same as that of the
phenothiazines, but it produces no side-effects worth
recording. No drowsiness, giddiness or extra-pyramidal
symptoms have been observed in this trial. It acts by
depressing the chemoreceptor tr.igger zone of the vomiting
centre in the medulla. Trimethobenzamide contains
dimethylaminoethoxy- and trimethoxybenzoyl groups; the
first chemical group is present in diphenhydramine, which
has been noted to cause central excitation as well as anti-
emesis. The second chemical group is contained in reser-
pine which, in the minimum anti-emetic dose, has been
proved to cause diarrhoea and lethargy.4,s But in trimetho-
benzamide the combination of these two chemical groups
results in a compound without excitatory or sedative
effects.s
Blood studies, urinalysis and transaminase levels have
shown no abnormalities attributable to the drug.6
THE TRIAL
During the early part of the trial only patients with actual
vomiting were treated with trimethobenzamide, since it was
thought that this drug would be of use only in patients w~th
this symptom, by virtue of the pharmacodynamic results
obtained by inhibition of the trigger zone in the medulla,
as reported by others. As the trial proceeded, however,
it became apparent that it was effective in cases where
nausea alone was present. It is most rewarding that this
trial has shown that it is a non-toxic, non-sedative drug
equally effective in nausea and in vomiting of pregnancy.
It is a highly specific drug.
All the patients in this survey were private patients seen
during their antenatal period. Slow release or timespan
tablets of 300 mg. were given by mouth, twice daily in the
average patient, increased to I.i.d. in those patients whose
symptoms were regarded a severe and therefore intractable
on the twice-daily dosage.
RESULTS
Poor 5 (The drug was eventually stopped and
other treatment, such as hospitalization,
etc., substituted)
Good 10 (where more than 24 tablets were re-
quired)
Excellent 20 (where 24 tablets or less were used)
Out of 35 patients, 30 reported that the drug had proved
beneficial. The 5 patients who. failed to respond all had
severe hyperemesis gravidarum, and it is our opinion that
if the intramuscular form of ·trimethobenzamide (200 mg.)
had been available, some of these patients with severe
symptoms would probably have responded to parenteral
therapy, allowing them to continue later on the oral form.
It is our intention to use the intramuscular Ioute in future
in all patients with severe hyperemesis, to make further
assessments of the efficacy of this drug.
SUMMARY
1. A clinical trial using trimethobenzamide is described
in patients with nausea and vomiting in pregnancy.
2. The drug has a definite place in obstetrics, as shown
by ,30 patients who obtained relief of their symptoms out
of a total of 35-a success rate of 85'7%.
3. It is gratifying to note that trimethobenzamide has
no side-effects when used in pregnant women, thus con-
stituting a great advance on other known anti-emetic drugs
which unfortunately have the drawback of causing various
undesirable side-effects, such as hypotension, drowsiness,
giddiness, and extra-pyramidal symptoms.
4. It is urged that this drug be the first choice when an
anti-nauseant or anti-emetic drug is indicated in nausea or
vomiting of pregnancy, because of the absence of side-
effects.
We wish to thank Messrs Roche Products (Pty.) Limited,
Johannesburg, for the generous supplies of 'tigan' (trirnetho-
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